CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Nature Cardiovascular Research, published by SpringerNature in Germany, stands as a premier journal dedicated to advancing the field of cardiovascular sciences. With an impressive 2023 categorization in the Q1 quartile across multiple disciplines—including Biochemistry, Genetics and Molecular Biology, Cardiology, and Medicine—this journal uniquely positions itself as a leading resource for pioneering research and innovative findings. Although currently not open access, it provides a rich repository of peer-reviewed articles that contribute directly to the evolving landscape of cardiovascular medicine. The journal aims to bridge the knowledge gap between basic science and clinical application, catering to researchers, healthcare professionals, and students alike who are immersed in the complexities of cardiovascular health. With robust Scopus rankings in key categories, Nature Cardiovascular Research is poised to shape future directions in the field, helping to foster a deeper understanding of cardiovascular diseases and their underlying mechanisms. Explore the latest research and be part of the conversation in one of the most impactful scientific domains.

DNA AND CELL BIOLOGY, published by Mary Ann Liebert, Inc, is a distinguished journal in the realms of cell biology, genetics, and molecular biology, holding a notable position in its Q3 and Q2 quartile rankings across multiple academic categories as of 2023. With an ISSN of 1044-5498 and an E-ISSN of 1557-7430, this journal has been a pivotal platform for the dissemination of cutting-edge research since its inception in 1990, extending its coverage through 2024. Situated in the United States, the journal offers high-quality peer-reviewed articles, exploring significant advancements in biological sciences while fostering interdisciplinary collaborations within the research community. Though it currently does not offer open access, subscribed institutions and individual readers benefit from its rich repository of knowledge. The journal's rigorous standards and impactful content make it an essential resource for researchers, professionals, and students alike, aiming to stay at the forefront of discoveries influencing DNA and cellular dynamics.

TISSUE & CELL is a prominent academic journal, published by CHURCHILL LIVINGSTONE, that has been at the forefront of research in the fields of cell biology, developmental biology, and miscellaneous areas of medicine since its inception in 1969. With a strong focus on high-quality research, TISSUE & CELL has established itself within the academic community, holding a Q3 ranking in both Cell Biology and Developmental Biology, and a Q2 ranking in Medicine as of 2023. The journal aims to disseminate significant findings that contribute to the understanding of tissue structure and function, helping to bridge the gap between basic biological research and clinical applications. While it operates on a subscription basis and does not currently offer Open Access options, the journal remains a vital resource for researchers, professionals, and students interested in cutting-edge developments in the biological sciences. The journal's address is located in the scenic city of Edinburgh, further establishing its academic heritage in the United Kingdom.

Cell and Bioscience is a prestigious open-access journal published by BMC that has been at the forefront of biochemistry, genetics, and molecular biology since its inception in 2011. With an impressive impact factor, this journal has established itself as a vital resource for researchers and professionals in these rapidly advancing fields, reflecting its high ranking of #29 out of 221 in the Scopus classification and placing it in the 87th percentile. Based in the United Kingdom, Cell and Bioscience aims to foster innovation and dissemination of research findings addressing critical biological questions through rigorous peer-reviewed articles and inter-disciplinary approaches. The journal's open-access model ensures unrestricted access to transformative research, promoting collaboration and knowledge sharing among academics, students, and practitioners worldwide. With a commitment to maintaining excellence in the field, Cell and Bioscience provides an essential platform for those looking to contribute to the evolving landscape of biosciences.

Current Stem Cell Research & Therapy, published by Bentham Science Publishers Ltd, is a leading journal dedicated to advancing the field of stem cell research. With an ISSN of 1574-888X and an E-ISSN of 2212-3946, this journal has been a valuable resource since its inception in 2006 and continues to broaden its scope through 2024. Recognized in the Q2 quartile for Medicine (miscellaneous) and ranked in the 66th percentile among its peers, the journal plays a crucial role in disseminating high-quality, peer-reviewed research that explores both the therapeutic and biological implications of stem cells. Located in the United Arab Emirates, Current Stem Cell Research & Therapy embraces a global audience of researchers, professionals, and students, providing a vibrant platform for discourse and innovation. While the journal offers subscription-based access, it remains committed to enhancing the scientific community's understanding of stem cell therapy and its applications across various medical fields.

European Journal of Pharmaceutics and Biopharmaceutics is a leading academic journal published by Elsevier, dedicated to advancing the field of pharmaceutical sciences through high-quality research. Established in 1991, this multidisciplinary journal offers a platform for the dissemination of innovative findings in pharmaceutics and biopharmaceutics, covering crucial aspects such as drug formulation, delivery systems, and the interface of pharmaceutical formulation with biological systems. The journal is well-regarded for its impact, earning a Q1 status in Pharmaceutical Science and consistent Q2 rankings in both Biotechnology and Medicine (Miscellaneous) categories in 2023, thereby highlighting its significance in the scientific community. With an impressive Scopus ranking of 26th percentile in Pharmaceutical Science and 60th percentile in Biotechnology, it positions itself firmly at the forefront of research, supporting researchers, professionals, and students in their quest to address complex health challenges. While the journal does not offer an open-access option, it facilitates a rigorous peer-review process, ensuring that published articles meet the highest standards of scientific integrity. For those looking to make meaningful contributions to the field, the European Journal of Pharmaceutics and Biopharmaceutics serves as an essential resource and reference point.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.